ResearcherShanghai Jiao Tong UniversityNo recent work listed
Weiyi Huang
Matched on ORCID iD 0000-0002-7992-3005; OpenAlex author ID A5013641001. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers
Papers 6
- Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Co-author DOI 10.1038/s41598-017-03153-6↗
- Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries. Co-author DOI 10.1097/mpa.0000000000000891↗
- Inhibitory effect of RNA-mediated knockdown of zinc finger protein 91 pseudogene on pancreatic cancer cell growth and invasion. Co-author DOI 10.3892/ol.2016.4794↗
- A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy. Co-author DOI 10.1007/s00432-015-1953-y↗
- FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep10081↗
- MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer… Co-author DOI 10.7314/apjcp.2013.14.12.7529↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Liwei Wang · 4 shared papers, 2013–2017 · strength 0.23
- Paper Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. DOI 10.1038/s41598-017-03153-6↗
- Paper FoxO1-negative cells are cancer stem-like cells in pancreatic ductal adenocarcinoma. DOI 10.1038/srep10081↗
- Paper A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative … DOI 10.1007/s00432-015-1953-y↗
- Junjie Hang · 2 shared papers, 2017 · strength 0.13
- Paper Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. DOI 10.1038/s41598-017-03153-6↗
- Paper Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort S… DOI 10.1097/mpa.0000000000000891↗
- Peng Xue · 2 shared papers, 2017 · strength 0.13
- Paper Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. DOI 10.1038/s41598-017-03153-6↗
- Paper Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort S… DOI 10.1097/mpa.0000000000000891↗
- Haiyan Yang · 2 shared papers, 2015–2017 · strength 0.12
- Paper Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. DOI 10.1038/s41598-017-03153-6↗
- Paper A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative … DOI 10.1007/s00432-015-1953-y↗
- Ning Li · 2 shared papers, 2015–2017 · strength 0.12
- Paper Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort S… DOI 10.1097/mpa.0000000000000891↗
- Paper A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative … DOI 10.1007/s00432-015-1953-y↗
- Weifeng Song · 2 shared papers, 2013–2015 · strength 0.11
- Lei Wang · 1 shared paper, 2016 · strength 0.08
- Yuzo Kodama · 1 shared paper, 2017 · strength 0.07
- Masashi Kanai · 1 shared paper, 2017 · strength 0.07
- Kyoichi Takaori · 1 shared paper, 2017 · strength 0.07
- Lei Wang · 1 shared paper, 2015 · strength 0.06
- Jiong Hu · 1 shared paper, 2015 · strength 0.05
- Peng Xue · 1 shared paper, 2015 · strength 0.05
- Lei Wang · 1 shared paper, 2013 · strength 0.04
- Jiujie Cui · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.